September 29, 2022 — Bloodstream levels of a protein fragment called endotrophin can be used to predict outcomes in patients with a common form of heart failure, according to a study co-led by researchers at the Perelman School of Medicine at the University of Pennsylvania. 

September 28, 2022 —  In the "TCT Innovation" session Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator, presented the new BIOMAG-I study results at the Transcatheter Cardiovascular Therapeutics (TCT) 2022.

September 28, 2022 —  A University of Massachusetts Amherst nurse engineer is leading a team of researchers who are developing a wearable vest system designed to monitor heart failure patients in their home and detect when their condition is worsening. 

September 28, 2022 —  Babies born with heart valve defects will have as many as 3 to 5 open heart surgeries before adulthood to replace prosthetics as they grow. Mortality and morbidity remain high, in part because there is no clinical standard for valve replacement in children under 5 years of age. 

September 28, 2022 — George Washington University researchers have found that post-stroke language and orientation impairments predicted recurrent stroke, while attention deficit impairment was associated with increased risk of death.


World Heart Day takes place each year on September 29. Founded in 2000 by the World Heart Federation, World Heart Day aims to increase awareness of heart disease and stroke worldwide.


September 27, 2022 —  Martha Gulati, MD, an expert in preventive cardiology and women’s heart disease, has joined the Smidt Heart Institute as director of Preventive Cardiology, associate director of the Preventive and Rehabilitative Cardiac Center and associate director of the Barbra Streisand Women’s Heart Center in the Depa

September 27, 2022 —  Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, reported that a late breaking abstract describing dose response data from its positive Phase 2 clinical study of istaroxime in early cardiogenic shock (SEISMiC) will be presented on October 2 at the 

Subscribe Now